JP2013544239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544239A5 JP2013544239A5 JP2013536694A JP2013536694A JP2013544239A5 JP 2013544239 A5 JP2013544239 A5 JP 2013544239A5 JP 2013536694 A JP2013536694 A JP 2013536694A JP 2013536694 A JP2013536694 A JP 2013536694A JP 2013544239 A5 JP2013544239 A5 JP 2013544239A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- pharmaceutical formulation
- purin
- cyclohexanol
- furanyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 38
- IBGLGMOPHJQDJB-IHRRRGAJSA-N chembl1950289 Chemical compound C1C[C@@H](O)CC[C@@H]1NC1=NC=C(N=C(NC=2C(=CC(F)=CC=2F)F)N2[C@@H]3COCC3)C2=N1 IBGLGMOPHJQDJB-IHRRRGAJSA-N 0.000 claims 20
- 239000012453 solvate Substances 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 19
- 125000001424 substituent group Chemical group 0.000 claims 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 14
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims 11
- 239000003085 diluting agent Substances 0.000 claims 8
- 239000007884 disintegrant Substances 0.000 claims 8
- 239000000314 lubricant Substances 0.000 claims 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 7
- 229960001681 croscarmellose sodium Drugs 0.000 claims 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 7
- 235000019359 magnesium stearate Nutrition 0.000 claims 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 6
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 6
- 229960001375 lactose Drugs 0.000 claims 6
- 239000008101 lactose Substances 0.000 claims 6
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 4
- 230000000155 isotopic effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010063209 Chronic allograft nephropathy Diseases 0.000 claims 1
- 201000001200 Crouzon syndrome-acanthosis nigricans syndrome Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010051920 Glomerulonephropathy Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 229960004977 anhydrous lactose Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003437 trachea Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40629210P | 2010-10-25 | 2010-10-25 | |
| US61/406,292 | 2010-10-25 | ||
| US201161481378P | 2011-05-02 | 2011-05-02 | |
| US61/481,378 | 2011-05-02 | ||
| US201161528427P | 2011-08-29 | 2011-08-29 | |
| US61/528,427 | 2011-08-29 | ||
| US201161537963P | 2011-09-22 | 2011-09-22 | |
| US61/537,963 | 2011-09-22 | ||
| PCT/US2011/057460 WO2012061061A1 (en) | 2010-10-25 | 2011-10-24 | Pharmaceutical formulations of a substituted diaminopurine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016088076A Division JP2016155854A (ja) | 2010-10-25 | 2016-04-26 | 置換されているジアミノプリンの薬学的製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013544239A JP2013544239A (ja) | 2013-12-12 |
| JP2013544239A5 true JP2013544239A5 (https=) | 2014-12-04 |
Family
ID=44913416
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013536694A Pending JP2013544239A (ja) | 2010-10-25 | 2011-10-24 | 置換されているジアミノプリンの薬学的製剤 |
| JP2016088076A Pending JP2016155854A (ja) | 2010-10-25 | 2016-04-26 | 置換されているジアミノプリンの薬学的製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016088076A Pending JP2016155854A (ja) | 2010-10-25 | 2016-04-26 | 置換されているジアミノプリンの薬学的製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8603527B2 (https=) |
| EP (1) | EP2632439B1 (https=) |
| JP (2) | JP2013544239A (https=) |
| KR (1) | KR20130142141A (https=) |
| CN (1) | CN103298454B (https=) |
| AU (1) | AU2011323807B2 (https=) |
| WO (1) | WO2012061061A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8603527B2 (en) * | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| US8680076B2 (en) | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| EP3185900A4 (en) | 2014-08-25 | 2018-05-02 | Aimmune Therapeutics, Inc. | Egg protein formulations and methods of manufacture thereof |
| US9512124B2 (en) | 2014-10-06 | 2016-12-06 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| HUE056631T2 (hu) * | 2016-04-01 | 2022-02-28 | Signal Pharm Llc | (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-PIRÁN-4-il)amino)-8-((2,4,6-triklorofenil)amino)-9H-purin- 9-il)-1-metil-ciklohexán-1-karboxamid és alkalmazási módszereik |
| MX379513B (es) | 2016-04-01 | 2025-03-11 | Signal Pharm Llc | Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. |
| CN106632339B (zh) * | 2016-12-16 | 2018-11-27 | 温州医科大学 | 一种6-取代-9h-嘌呤类衍生物及其制备方法和应用 |
| KR20190138871A (ko) * | 2017-04-24 | 2019-12-16 | 사무스 테라퓨틱스, 인코포레이티드 | Hsp90 저해제 경구 제형 및 관련 방법 |
| AU2018345647A1 (en) | 2017-10-04 | 2020-04-16 | Celgene Corporation | Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide |
| CN111417634A (zh) | 2017-10-04 | 2020-07-14 | 细胞基因公司 | 用于制备顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的方法 |
| CN110921918B (zh) * | 2019-12-18 | 2021-12-31 | 山东理工大学 | 氨基芳磺酸类废水的处理方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| FI109088B (fi) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| NZ555909A (en) * | 2004-12-13 | 2009-11-27 | Mcneil Ppc Inc | Compositions and methods for reducing the degradation of phenylephrine by oxygen |
| US7759342B2 (en) | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| WO2007062338A2 (en) | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Solid formulations |
| CA2667345C (en) | 2006-10-27 | 2016-03-22 | Signal Pharmaceuticals, Llc | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith |
| ES2400006T3 (es) * | 2008-04-23 | 2013-04-04 | Farmasierra Manufacturing, S.L. | Formulación farmacéutica mejorada a base de ibuprofeno y codeína |
| WO2011071491A1 (en) | 2009-12-09 | 2011-06-16 | Signal Pharmaceuticals, Llc | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US8603527B2 (en) * | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| US8680076B2 (en) | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
-
2011
- 2011-10-20 US US13/277,615 patent/US8603527B2/en active Active
- 2011-10-24 WO PCT/US2011/057460 patent/WO2012061061A1/en not_active Ceased
- 2011-10-24 JP JP2013536694A patent/JP2013544239A/ja active Pending
- 2011-10-24 EP EP11779917.1A patent/EP2632439B1/en not_active Not-in-force
- 2011-10-24 CN CN201180062649.0A patent/CN103298454B/zh not_active Expired - Fee Related
- 2011-10-24 KR KR1020137013161A patent/KR20130142141A/ko not_active Ceased
- 2011-10-24 AU AU2011323807A patent/AU2011323807B2/en not_active Ceased
-
2013
- 2013-11-08 US US14/074,765 patent/US9198866B2/en active Active
-
2016
- 2016-04-26 JP JP2016088076A patent/JP2016155854A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013544239A5 (https=) | ||
| US20150306226A1 (en) | Composition | |
| TWI662962B (zh) | 治療癌症之方法 | |
| US10954223B2 (en) | Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof | |
| JP2005194283A5 (https=) | ||
| TWI750143B (zh) | 含有2-{4-[n-(5,6-二苯基吡-2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物 | |
| JP2017501140A5 (https=) | ||
| TWI660748B (zh) | 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液 | |
| JP2018065876A (ja) | ニロチニブと選択された共結晶体を含有する多成分結晶系 | |
| JP2017528503A5 (https=) | ||
| JP2017528506A5 (https=) | ||
| JP2016534063A5 (https=) | ||
| JP2016505019A5 (https=) | ||
| RU2010114011A (ru) | Терапевтическое применение пептида yglf и сочетания с kvlpvpq | |
| JP2013526491A (ja) | メチソシルデナフィル・クエン酸塩結晶型ｏ及びその調製方法並びに応用 | |
| US20210308104A1 (en) | Pharmaceutical composition comprising eltrombopag olamine | |
| JP6839708B2 (ja) | ８−［（３ｒ）−３−アミノ−１−ピペリジニル］−７−（２−ブチン−１−イル）−３，７−ジヒドロ−３−メチル−１−［４−メチル−２−キナゾリニル）メチル］−１ｈ−プリン−２，６−ジオンまたは薬学上許容できるその塩を含有する医薬組成物 | |
| JP2024518685A5 (https=) | ||
| US20170007602A1 (en) | Pharmaceutical dosage forms | |
| TW200927118A (en) | Treatment of vasomotor symptoms | |
| FI4313058T3 (fi) | Roginolisibia käsittävä koostumus ja annosteluohjelma syövän tai tulehdus- tai autoimmunisairauden hoitoon | |
| JP2010501520A5 (https=) | ||
| WO2013151518A1 (en) | Capsule formulations comprising ceftibuten | |
| KR20200024237A (ko) | 약학 조성물 및 이를 제조하기 위한 방법 | |
| JP6130595B2 (ja) | ピロロキノリンキノンリチウム塩の結晶体及び調製方法と応用 |